PETACH TIKVA, Israel--(EON: Enhanced Online News)--Can-Fite
BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology
company advancing a pipeline of proprietary small molecule drugs that
address cancer, liver and inflammatory diseases, today announced that
its CEO Dr. Pnina Fishman will join other global thought-leaders in the
field of non-alcoholic steatohepatitis (NASH) to speak at NASH
Summit Europe in Frankfurt, Germany on October 12, 2017. She will
deliver her presentation titled, “The Anti-Fibrogenic and Liver
Protective Effects of Namodenoson (CF102): From Preclinical to Human
Studies” at 1:00pm on Thursday, October 12, 2017.

“I am pleased to be invited to speak at NASH Summit Europe and to share
Can-Fite’s expertise in the development of a novel therapy for the
treatment of NASH and its precursor, non-alcoholic fatty liver disease
(NAFLD). As NASH/NAFLD impacts a growing number of people, the industry
is coming together in summits like this to accelerate the path to
developing and bringing to market effective diagnostics and treatments
for patients living with this disease,” Dr. Fishman stated.

Can-Fite’s liver drug candidate Namodenoson (CF102) is set to commence a
Phase II trial to determine the efficacy and safety of the drug in the
treatment of NASH/NAFLD. The trial will enroll approximately 60 patients
with NAFLD, with or without NASH. Patients will be enrolled in three
arms, including two different dosages of Namodenoson and a placebo,
given via oral tablets twice daily. The study's primary endpoints will
be percent change from baseline in liver triglyceride (fat)
concentration measured by nuclear magnetic resonance spectroscopy (NMRS)
and safety.

About NAFLD/NASH

NAFLD is characterized by excess fat accumulation in the form of
triglycerides (steatosis) in the liver. According to a study published
in Hepatology, an estimated 17%-33% of the population in the U.S. has
NAFLD, with a higher prevalence in people with type II diabetes.
Incidence is increasing based on rising obesity rates. NAFLD includes a
range of liver diseases, with NASH being the more advanced form,
manifesting as hepatic injury and inflammation. According to the NIH,
the incidence of NASH in the U.S. is believed to affect 2-5% of the
population. The spectrum of NAFLDs resembles alcoholic liver disease;
however, they occur in people who drink little or no alcohol. If
untreated, NASH can lead to cirrhosis and liver cancer. By 2025, the
addressable pharmaceutical market for NASH is estimated to reach $35-40
billion.

About Namodenoson (CF102)

Namodenoson is a small orally bioavailable drug that binds with high
affinity and selectivity to the A3 adenosine receptor (A3AR).
Namodenoson is being evaluated in Phase II trials for two indications,
as a second line treatment for hepatocellular carcinoma, and as a
treatment for non-alcoholic fatty liver disease (NAFLD) and
non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in
diseased cells whereas low expression is found in normal cells. This
differential effect accounts for the excellent safety profile of the
drug. Can-Fite has received Orphan Drug Designation for Namodenoson in
Europe and the U.S., as well as Fast Track Status in the U.S. as a
second line treatment for hepatocellular carcinoma.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced
clinical stage drug development Company with a platform technology that
is designed to address multi-billion dollar markets in the treatment of
cancer, inflammatory disease and sexual dysfunction. The Company's lead
drug candidate, Piclidenoson, is scheduled to enter a Phase III trial
for rheumatoid arthritis in 2017 and a Phase III trial for psoriasis in
early 2018. The rheumatoid arthritis Phase III protocol has recently
been agreed with the European Medicines Agency. Can-Fite's liver cancer
drug CF102 is in Phase II trials for patients with liver cancer and is
slated to enter Phase II for the treatment of non-alcoholic
steatohepatitis (NASH). CF102 has been granted Orphan Drug Designation
in the U.S. and Europe and Fast Track Designation as a second line
treatment for hepatocellular carcinoma by the U.S. Food and Drug
Administration. CF102 has also shown proof of concept to potentially
treat other cancers including colon, prostate, and melanoma. CF602, the
Company's third drug candidate, has shown efficacy in the treatment of
erectile dysfunction in preclinical studies and the Company is
investigating additional compounds, targeting A3AR, for the treatment of
sexual dysfunction. These drugs have an excellent safety profile with
experience in over 1,000 patients in clinical studies to date. For more
information please visit: www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about
Can-Fite's expectations, beliefs or intentions regarding, among other
things, market risks and uncertainties, its product development efforts,
business, financial condition, results of operations, strategies or
prospects. In addition, from time to time, Can-Fite or its
representatives have made or may make forward-looking statements, orally
or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as "believe," "expect," "intend," "plan,"
"may," "should" or "anticipate" or their negatives or other variations
of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters.
These forward-looking statements may be included in, but are not limited
to, various filings made by Can-Fite with the U.S. Securities and
Exchange Commission, press releases or oral statements made by or with
the approval of one of Can-Fite's authorized executive officers.
Forward-looking statements relate to anticipated or expected events,
activities, trends or results as of the date they are made. Because
forward-looking statements relate to matters that have not yet occurred,
these statements are inherently subject to risks and uncertainties that
could cause Can-Fite's actual results to differ materially from any
future results expressed or implied by the forward-looking statements.
Many factors could cause Can-Fite's actual activities or results to
differ materially from the activities and results anticipated in such
forward-looking statements. Factors that could cause our actual results
to differ materially from those expressed or implied in such
forward-looking statements include, but are not limited to: the
initiation, timing, progress and results of our preclinical studies,
clinical trials and other product candidate development efforts; our
ability to advance our product candidates into clinical trials or to
successfully complete our preclinical studies or clinical trials; our
receipt of regulatory approvals for our product candidates, and the
timing of other regulatory filings and approvals; the clinical
development, commercialization and market acceptance of our product
candidates; our ability to establish and maintain corporate
collaborations; the implementation of our business model and strategic
plans for our business and product candidates; the scope of protection
we are able to establish and maintain for intellectual property rights
covering our product candidates and our ability to operate our business
without infringing the intellectual property rights of others; estimates
of our expenses, future revenues, capital requirements and our needs for
additional financing; competitive companies, technologies and our
industry; statements as to the impact of the political and security
situation in Israel on our business; and risks and other risk factors
detailed in Can-Fite's filings with the SEC and in its periodic filings
with the TASE. In addition, Can-Fite operates in an industry sector
where securities values are highly volatile and may be influenced by
economic and other factors beyond its control. Can-Fite does not
undertake any obligation to publicly update these forward-looking
statements, whether as a result of new information, future events or
otherwise.